Ignyta Signs Rheumatoid Arthritis Research Collaboration with Leiden
University Medical Center
SAN DIEGO -- February 25, 2013
Ignyta, Inc., the personalized medicine company dedicated to improving the
diagnosis and treatment of patients with rheumatoid arthritis (RA), lupus and
other autoimmune diseases, announced today a collaboration with Leiden
University Medical Center (LUMC) to assess the epigenetic signatures of
patients with early synovitis and rheumatoid arthritis.
“With the signing of this collaboration with LUMC, Ignyta now has a global
reach to study patients with undifferentiated arthritis and rheumatoid
arthritis, taking us another step closer to achieving our goal of developing a
diagnostic assay for patients with early RA,” said Jonathan Lim, M.D.,
co-founder, chairman and CEO of Ignyta. “LUMC is one of the world’s leading
institutions in researching and treating patient with arthritis, and we are
pleased to be collaborating with them in this important area of research.”
Professor Tom Huizinga, Head of the Department of Rheumatology at LUMC, said,
“Ignyta is pioneering a very interesting technological approach to try to
detect early RA. We are excited to be working with them in an effort to
improve care for RA patients.”
About RA Diagnosis
Many well-controlled longitudinal studies demonstrate that early detection and
treatment of RA leads to improved long-term health outcomes. However, RA can
be a difficult disease to differentially diagnose early in its progression.
There are no currently available biomarker-based diagnostic tests that have
both high specificity and high sensitivity for detecting early RA. Ignyta is
employing its epigenomic technologies to develop an epigenetic-based
diagnostic test with both high specificity and high sensitivity for detection
of early RA.
About Ignyta, Inc.
Ignyta, Inc., located in San Diego, California, is a personalized medicine
company developing revolutionary new products and services to customize
diagnosis and treatment of patients with rheumatoid arthritis, lupus and other
The company was launched in August 2011 by Jonathan E. Lim, M.D., former
president, CEO, and board director of Halozyme Therapeutics, Inc., and Gary S.
Firestein, M.D., director of the Clinical and Translational Research Institute
and Dean and Associate Vice Chancellor of Translational Medicine at UC San
Diego. Ignyta is a trailblazer in the application of “omics” technologies
integrated with bioinformatics to the development and commercialization of
novel biomarkers and tests for diagnostic and therapeutic applications in
The scientific discoveries that fueled the founding of Ignyta were published
in July 2012 in the Annals of the Rheumatic Diseases (http://bit.ly/QOZ8Zr).
In 2012, the company successfully closed a $5.5 million Series B financing led
by City Hill Ventures, LLC (http://www.cityhillventures.com/) and Colt
Ventures (http://www.coltventures.com/), and a $500,000 capital term loan from
Silicon Valley Bank (http://www.svb.com/). For more information, please visit:
Ignyta Media and Investor Contact:
Zachary Hornby, 858-369-5732
Press spacebar to pause and continue. Press esc to stop.